LipidMetabolism and Cardiovascular Risk in HIV-1 Infection and HAART : Present and Future Problems
暂无分享,去创建一个
[1] C. Fichtenbaum,et al. Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy , 2010, AIDS.
[2] C. Katlama,et al. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients. , 2010, The Journal of antimicrobial chemotherapy.
[3] J. Absalon,et al. Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study , 2010, Journal of acquired immune deficiency syndromes.
[4] O. Kirk,et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. , 2010, The Journal of infectious diseases.
[5] P. Reiss,et al. Abacavir and cardiovascular risk , 2010, Current opinion in infectious diseases.
[6] D. Cooper,et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials , 2010, The Lancet.
[7] Lynne Peeples,et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. , 2009, The New England journal of medicine.
[8] K. Ruxrungtham,et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis , 2009, AIDS.
[9] D. Podzamczer,et al. A Simplification Trial Switching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1-Infected Patients With Virological Suppression , 2009, Journal of acquired immune deficiency syndromes.
[10] J. Molina,et al. Improvement in Lipid Profiles in Antiretroviral-Experienced HIV-Positive Patients With Hyperlipidemia After a Switch to Unboosted Atazanavir , 2009, Journal of acquired immune deficiency syndromes.
[11] D. Podzamczer,et al. Efficacy and Safety of Switching From Boosted Lopinavir to Boosted Atazanavir in Patients With Virological Suppression Receiving a LPV/r-Containing HAART: The ATAZIP Study , 2009, Journal of acquired immune deficiency syndromes.
[12] D. Ward,et al. Gemini: A Noninferiority Study of Saquinavir/Ritonavir Versus Lopinavir/Ritonavir as Initial HIV-1 Therapy in Adults , 2009, Journal of acquired immune deficiency syndromes.
[13] B. Gazzard,et al. Prevention of atherosclerosis in patients living with HIV , 2009, Vascular health and risk management.
[14] D. Francisci,et al. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction , 2009, AIDS (London).
[15] A. Go,et al. Response to Newly Prescribed Lipid-Lowering Therapy in Patients With and Without HIV Infection , 2009, Annals of Internal Medicine.
[16] S. Sauleda,et al. Improvements in Subcutaneous Fat, Lipid Profile, and Parameters of Mitochondrial Toxicity in Patients with Peripheral Lipoatrophy When Stavudine is Switched to Tenofovir (LIPOTEST Study) , 2008, HIV clinical trials.
[17] M. González-Tomé,et al. Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children , 2008, BMC infectious diseases.
[18] Suraiya Rasheed,et al. HIV Replication Enhances Production of Free Fatty Acids, Low Density Lipoproteins and Many Key Proteins Involved in Lipid Metabolism: A Proteomics Study , 2008, PloS one.
[19] R. Parker,et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. , 2008, Journal of the American College of Cardiology.
[20] M. Hersberger,et al. Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial , 2008, Heart.
[21] C. Sabin,et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. , 2008, Circulation.
[22] B. Hirschel,et al. Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy. , 2008, The Journal of antimicrobial chemotherapy.
[23] D. Katzenstein,et al. Metabolic and Immune Activation Effects of Treatment Interruption in Chronic HIV-1 Infection: Implications for Cardiovascular Risk , 2008, PloS one.
[24] J. Gerber,et al. Drug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers , 2008, Journal of acquired immune deficiency syndromes.
[25] J. Berman,et al. Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease. , 2008, The American journal of pathology.
[26] C. Fichtenbaum,et al. Fish Oil and Fenofibrate for the Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy: Results of ACTG A5186 , 2008, Journal of acquired immune deficiency syndromes.
[27] M. Rodriguez‐Barradas,et al. Lipid‐Lowering Efficacy and Safety After Switching to Atazanavir‐Ritonavir‐Based Highly Active Antiretroviral Therapy in Patients with Human Immunodeficiency Virus , 2008, Pharmacotherapy.
[28] Harpreet S. Pannu,et al. Long-term cocaine use and antiretroviral therapy are associated with silent coronary artery disease in African Americans with HIV infection who have no cardiovascular symptoms. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] D. Margolis,et al. Improvement in Insulin Sensitivity and Dyslipidemia in Protease Inhibitor-Treated Adult Male Patients After Switch to Atazanavir/Ritonavir , 2008, Journal of Investigative Medicine.
[30] V. Soriano,et al. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. , 2007, The Journal of antimicrobial chemotherapy.
[31] A. Cheng,et al. The Safety and Efficacy of Switching Stavudine to Tenofovir DF in Combination with Lamivudine and Efavirenz in HIV-1—Infected Patients: Three-Year Follow–up After Switching Therapy , 2007, HIV clinical trials.
[32] P. Reiss,et al. Pharmacokinetics and Pharmacodynamics of Combined use of Lopinavir/Ritonavir and Rosuvastatin in HIV-Infected Patients , 2007, Antiviral therapy.
[33] J. Parienti,et al. Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[34] G. Bondy,et al. Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV , 2007, Lipids in Health and Disease.
[35] M. Moroni,et al. First Italian Consensus Statement on Diagnosis, Prevention and Treatment of Cardiovascular Complications in HIV-infected Patients in the HAART Era (2006) , 2007, Infection.
[36] A. Collier,et al. Switching to a Protease Inhibitor-Containing, Nucleoside-Sparing Regimen (Lopinavir/Ritonavir Plus Efavirenz) Increases Limb Fat But Raises Serum Lipid Levels: Results of a Prospective Randomized Trial (AIDS Clinical Trial Group 5125s) , 2007, Journal of acquired immune deficiency syndromes.
[37] C. Leen,et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[38] A. León,et al. Incidence and causes of death in HIV‐infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area , 2007, HIV medicine.
[39] C. Katlama,et al. Reduction in Triglyceride Level With N-3 Polyunsaturated Fatty Acids in HIV-Infected Patients Taking Potent Antiretroviral Therapy: A Randomized Prospective Study , 2007, Journal of acquired immune deficiency syndromes.
[40] F. Goebel,et al. Metabolic and anthropometric changes one year after switching from didanosine/stavudine to tenofovir in HIV-infected patients. , 2007, European journal of medical research.
[41] G. Rizzardini,et al. Switch to abacavir-based triple nucleoside regimens in HIV-1 infected patients never treated with suboptimal antiretroviral therapy: a review. , 2006, Medical science monitor : international medical journal of experimental and clinical research.
[42] B. Clotet,et al. Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins , 2006, AIDS.
[43] D. Ward,et al. Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. , 2006, AIDS patient care and STDs.
[44] C. Katlama,et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial , 2006, The Lancet.
[45] S. Moreno,et al. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir , 2006, AIDS.
[46] Ò. Miró,et al. The Impact of Reducing Stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients , 2006, Antiviral therapy.
[47] J. Aberg,et al. Dyslipidemia in HIV patients. , 2005, Cleveland Clinic journal of medicine.
[48] G. Aldrovandi,et al. Improvement in Dyslipidaemia after Switching Stavudine to Tenofovir and Replacing Protease Inhibitors with Efavirenz in HIV-Infected Children , 2005, Antiviral therapy.
[49] W. K. Henry,et al. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. , 2005, AIDS research and human retroviruses.
[50] C. Fichtenbaum,et al. Effect of Efavirenz on the Pharmacokinetics of Simvastatin, Atorvastatin, and Pravastatin: Results of AIDS Clinical Trials Group 5108 Study , 2005, Journal of acquired immune deficiency syndromes.
[51] R. Schmidt,et al. Switching to Atazanavir Improves Metabolic Disorders in Antiretroviral-Experienced Patients With Severe Hyperlipidemia , 2005, Journal of acquired immune deficiency syndromes.
[52] Jeffrey L. Anderson. Infection, antibiotics, and atherothrombosis--end of the road or new beginnings? , 2005, The New England journal of medicine.
[53] E. Dejesus,et al. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment , 2005, BMC infectious diseases.
[54] P. Gambert,et al. Serum adiponectin and metabolic parameters in HIV‐1‐infected patients after substitution of nevirapine for protease inhibitors , 2004, European journal of clinical investigation.
[55] L. Broxmeyer. Heart disease: the greatest 'risk' factor of them all. , 2004, Medical hypotheses.
[56] W. K. Henry,et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[57] B. Gazzard,et al. Comparison of metabolic abnormalities 48 weeks after switching from highly active antiretroviral therapy containing a non-nucleoside reverse transcriptase inhibitor to Trizivir versus continued highly active antiretroviral therapy , 2003, AIDS (London).
[58] S. Cole,et al. Impact of HIV infection and HAART on serum lipids in men. , 2003, JAMA.
[59] M. Johnson,et al. Comparison of Metabolic Abnormalities and Clinical Lipodystrophy 48 Weeks After Switching from HAART to Trizivir™ Versus Continued HAART: The Trizal Study , 2003, HIV clinical trials.
[60] Dannae Brown,et al. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia , 2002, AIDS.
[61] M. Serrano-Ríos,et al. Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[62] R. Paredes,et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[63] B. Gazzard,et al. Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy , 2001, AIDS.
[64] R. Paredes,et al. Antiretroviral Treatment Simplification With Nevirapine in Protease Inhibitor‐Experienced Patients With HIV‐Associated Lipodystrophy: 1‐Year Prospective Follow‐Up of a Multicenter, Randomized, Controlled Study , 2001, Journal of acquired immune deficiency syndromes.
[65] A. Quyyumi,et al. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. , 2000, The American journal of cardiology.
[66] Jianhui Zhu,et al. Infection and atherosclerosis: emerging mechanistic paradigms. , 1999, Circulation.
[67] P. Jousilahti,et al. Enterovirus infections as a possible risk factor for myocardial infarction. , 1998, Circulation.
[68] H. Jick,et al. Acute respiratory-tract infections and risk of first-time acute myocardial infarction , 1998, The Lancet.
[69] M. Nieminen,et al. Role of infection as a risk factor for atherosclerosis, myocardial infarction, and stroke. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[70] J. Danesh,et al. Chronic infections and coronary heart disease: is there a link? , 1997, The Lancet.
[71] L. Barbara,et al. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. , 1997, Archives of internal medicine.
[72] C. Grunfeld,et al. Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. , 1993, The Journal of clinical endocrinology and metabolism.
[73] K. Feingold,et al. Tumor Necrosis Factor, Interleukin, and Interferon Induced Changes in Lipid Metabolism as Part of Host Defense , 1992, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[74] W. Howard. Class of Antiretroviral Drugs and the Risk of Myocardial Infarction , 2008 .
[75] J. R. Arribas López. [Secondary effects of treatment with maraviroc and other CCR5 antagonists. Potential impact of the CCR5 blocker]. , 2008, Enfermedades Infecciosas y Microbiologia Clinica.
[76] G. Wassmer,et al. Improved lipid profiles and maintenance of virologic control in heavily pretreated HIV-infected patients who switched from stavudine to tenofovir treatment. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[77] J. Bartlett. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection , 2004 .
[78] C. Fichtenbaum,et al. Interactions Between Antiretroviral Drugs and Drugs Used for the Therapy of the Metabolic Complications Encountered During HIV Infection , 2002, Clinical pharmacokinetics.
[79] M. Leinonen,et al. Evidence for infectious agents in cardiovascular disease and atherosclerosis. , 2002, The Lancet. Infectious diseases.
[80] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.